Ben Bronstein
Director/Board Member at ALDEYRA THERAPEUTICS, INC.
Net worth: 92 371 $ as of 2024-03-30
Profile
Ben R.
Bronstein is the founder of Peptimmune, Inc. (1995), OPKO Health, Inc. (2008), Vidus Ocular, Inc. (2006), and Access BridgeGap Ventures (2011).
He is also the founder of BioSurface Technology, Inc. Dr. Bronstein's current jobs include Chairman at Cleveland Diagnostics, Inc., Independent Director at Aldeyra Therapeutics, Inc. (2010-present), Director at Helio Vision, Inc., and Principal at Cold Spring Venture Advisors LLC.
Dr. Bronstein's former jobs include Managing Director at Zero Stage Capital Co., Inc. (2003-2005), Director at eXIthera Pharmaceuticals, Inc., Executive Vice President-Clinical Development at Aclaris Therapeutics, Inc., and Advisor at Echelon Ventures.
He was also Chief Medical Officer at Sentien Biotechnologies, Inc. (2016-2017) and Stealth BioTherapeutics Corp.
(2014-2015).
Dr. Bronstein received his undergraduate, MBA, and doctorate degrees from Boston University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2023-06-29 | 28,248 ( 0.05% ) | 92 371 $ | 2024-03-30 |
Ben Bronstein active positions
| Companies | Position | Start |
|---|---|---|
| ALDEYRA THERAPEUTICS, INC. | Director/Board Member | 2010-05-31 |
Cold Spring Venture Advisors LLC
 Cold Spring Venture Advisors LLC Investment ManagersFinance Cold Spring Venture Advisors LLC provides investment management services. The private company is based in Newton, MA. | Corporate Officer/Principal | - |
Cleveland Diagnostics, Inc.
 Cleveland Diagnostics, Inc. Investment Trusts/Mutual FundsMiscellaneous Cleveland Diagnostics, Inc. develops and commercializes cancer diagnostics and screening tests. Its portfolio of non-invasive cancer diagnostic tests includes blood-based tests to screen for prostate, breast, and ovarian cancer. The company was founded by Arnon Chait and Boris Zaslavsky in October 2013 and is headquartered in Cleveland, OH. | Chairman | - |
Helio Vision, Inc.
 Helio Vision, Inc. Pharmaceuticals: MajorHealth Technology Helio Vision, Inc. operates as a biotechnology company. It develops a therapy for fibroproliferative disorders that lead to abnormal scarring and blindness after retina surgery. The company was founded by Josef H. von Rickenbach, Dean Eliott and Tomasz P. Stryjewski in 2016 and is headquartered in Waltham, MA. | Director/Board Member | - |
Former positions of Ben Bronstein
| Companies | Position | End |
|---|---|---|
| ACLARIS THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 2018-11-30 |
Sentien Biotechnologies, Inc.
 Sentien Biotechnologies, Inc. BiotechnologyHealth Technology Sentien Biotechnologies, Inc. develops cell-based therapy for critical care. It provides the Sentinel, a device that actively treats patients during a dialysis dose by supplementing patient blood with MSC-derived secretions. The company was founded by Brian Miller and Biju Parekkadan and is headquartered in Lexington, MA. | Corporate Officer/Principal | 2016-12-31 |
| STEALTH BIOTHERAPEUTICS CORP | Chief Tech/Sci/R&D Officer | 2015-07-31 |
Access BridgeGap Ventures
 Access BridgeGap Ventures Investment ManagersFinance Founded in 2011, Access BridgeGap Ventures is a venture capital firm located in Cambridge, Massachusetts. The firm is the life sciences venture capital investment arm of Access Industries, Inc. | Founder | 2013-10-09 |
Peptimmune, Inc.
 Peptimmune, Inc. BiotechnologyHealth Technology Peptimmune was founded in 2002 with technology from the laboratories of Dr. Jack Strominger, Higgins Professor of Biochemistry at Harvard University; and Dr. Hidde Ploegh, from the Whitehead Institute for Biomedical Research. Peptimmune has therapeutics in clinical development for the treatment of multiple sclerosis. Peptimmune's flagship program in multiple sclerosis features PI-2301, which has the opportunity to replace Copaxone® (Teva Pharmaceuticals), the world's leading first-line therapy for the treatment of MS. Peptimmune has broad expertise in MHC Class II molecules and their role in antigen presentation and modulation of immune responses. The Company exploits its proprietary DEEP Technology (Directed Expansion of Epitope Permutation) to design peptides and peptide mixtures for development as therapeutics, diagnostic kits, and as reagents for antibody generation. The Company is building a unique suite of expertise in the manufacture and control of peptide copolymer-based drug products. | Founder | 2011-10-26 |
Training of Ben Bronstein
| Boston University | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| ALDEYRA THERAPEUTICS, INC. | Health Technology |
| ACLARIS THERAPEUTICS, INC. | Health Technology |
| OPKO HEALTH, INC. | Health Services |
| Private companies | 12 |
|---|---|
Zero Stage Capital Co., Inc.
 Zero Stage Capital Co., Inc. Investment ManagersFinance Founded in 1981, Zero Stage Capital Co., Inc. is a venture capital firm headquartered in Cambridge, Massachusetts. | Finance |
eXIthera Pharmaceuticals, Inc.
 eXIthera Pharmaceuticals, Inc. BiotechnologyHealth Technology eXIthera Pharmaceuticals, Inc. develops and manufactures stroke prevention and antithrombosis drugs. Its drugs are based on the pathophysiological role of Factor XI in the initiation of intravascular thrombi without causing undue bleeding. The firm’s drug candidates are small, orally active, and highly selective Factor XI inhibitors. The company was founded by Neil J. Hayward and Frans L. Stassen in 2012 and is headquartered in Westborough, MA. | Health Technology |
BioSurface Technology, Inc.
 BioSurface Technology, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Sanofi, BioSurface Technology, Inc. is a commercial biotechnical research company. The private company is based in Cambridge, MA. The company was founded by David L. Castaldi, Ben R. Bronstein. BioSurface Technology was acquired by Genzyme Corp., part of Sanofi from April 08, 2011 on December 16, 1994. | Commercial Services |
Peptimmune, Inc.
Peptimmune, Inc. BiotechnologyHealth Technology Peptimmune was founded in 2002 with technology from the laboratories of Dr. Jack Strominger, Higgins Professor of Biochemistry at Harvard University; and Dr. Hidde Ploegh, from the Whitehead Institute for Biomedical Research. Peptimmune has therapeutics in clinical development for the treatment of multiple sclerosis. Peptimmune's flagship program in multiple sclerosis features PI-2301, which has the opportunity to replace Copaxone® (Teva Pharmaceuticals), the world's leading first-line therapy for the treatment of MS. Peptimmune has broad expertise in MHC Class II molecules and their role in antigen presentation and modulation of immune responses. The Company exploits its proprietary DEEP Technology (Directed Expansion of Epitope Permutation) to design peptides and peptide mixtures for development as therapeutics, diagnostic kits, and as reagents for antibody generation. The Company is building a unique suite of expertise in the manufacture and control of peptide copolymer-based drug products. | Health Technology |
Echelon Ventures
 Echelon Ventures Investment ManagersFinance Echelon Ventures (Echelon Ventures) is a venture capital firm founded in 2000 by Woody S Woodworth and Scott C McCabe. The firm is headquartered in Waltham, Massachusetts. | Finance |
Vidus Ocular, Inc.
 Vidus Ocular, Inc. Medical SpecialtiesHealth Technology Part of OPKO Health, Inc., Vidus Ocular, Inc. is a private company that manufactures shunts to treat glaucoma. The company is based in New Haven, CT. Vidus Ocular was acquired by OPKO Health, Inc. on May 07, 2008 for $2.71 million. The company was founded by James R. McNab, Ben R. Bronstein. | Health Technology |
Access BridgeGap Ventures
Access BridgeGap Ventures Investment ManagersFinance Founded in 2011, Access BridgeGap Ventures is a venture capital firm located in Cambridge, Massachusetts. The firm is the life sciences venture capital investment arm of Access Industries, Inc. | Finance |
Cleveland Diagnostics, Inc.
Cleveland Diagnostics, Inc. Investment Trusts/Mutual FundsMiscellaneous Cleveland Diagnostics, Inc. develops and commercializes cancer diagnostics and screening tests. Its portfolio of non-invasive cancer diagnostic tests includes blood-based tests to screen for prostate, breast, and ovarian cancer. The company was founded by Arnon Chait and Boris Zaslavsky in October 2013 and is headquartered in Cleveland, OH. | Miscellaneous |
Helio Vision, Inc.
Helio Vision, Inc. Pharmaceuticals: MajorHealth Technology Helio Vision, Inc. operates as a biotechnology company. It develops a therapy for fibroproliferative disorders that lead to abnormal scarring and blindness after retina surgery. The company was founded by Josef H. von Rickenbach, Dean Eliott and Tomasz P. Stryjewski in 2016 and is headquartered in Waltham, MA. | Health Technology |
Cold Spring Venture Advisors LLC
Cold Spring Venture Advisors LLC Investment ManagersFinance Cold Spring Venture Advisors LLC provides investment management services. The private company is based in Newton, MA. | Finance |
Stealth BioTherapeutics Corp.
 Stealth BioTherapeutics Corp. BiotechnologyHealth Technology Stealth BioTherapeutics Corp. is a clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. The company was founded on April 3, 2006 and is headquartered in Needham, MA. | Health Technology |
Sentien Biotechnologies, Inc.
Sentien Biotechnologies, Inc. BiotechnologyHealth Technology Sentien Biotechnologies, Inc. develops cell-based therapy for critical care. It provides the Sentinel, a device that actively treats patients during a dialysis dose by supplementing patient blood with MSC-derived secretions. The company was founded by Brian Miller and Biju Parekkadan and is headquartered in Lexington, MA. | Health Technology |
- Stock Market
- Insiders
- Ben Bronstein
